HYDRAZINE SULFATE for cancer - virtually no significant untoward side effects

[Guest guest]

http://scri.ngen.com/HYDRAZINE SULFATE"...Since hydrazine sulfate provided relief of a wide spectrum of cancer symptoms, it may be recommended for patients with end-stage cancer....virtually no significant untoward side effects..." The Syracuse Cancer Research Institute is a charitable, educational and scientific organization, tax-exempt under section 501©(3) of the Internal Revenue Code. SCRI expense distribution averages 92% for research, 4% for fund raising and 4% for management and general. For a copy of our Annual Report, write: Attorney General, Charities Bureau, 120 Broadway, New York, NY 10271; or Syracuse Cancer Research Institute, 600 East Genesee Street, Syracuse, NY 13202.The Syracuse Cancer Research Institute does not receive any funds in regard to its hydrazine sulfate activities and does not market, sell or distribute this drug. The institute is wholly dependent for its funding on contributions from the public—from foundations, business and industry and concerned individuals—and asks your help in sustaining its life-expanding programs. Your tax-deductible contributions are vital to this effort and serve to enhance the welfare and lives of cancer patients everywhere.All gifts will be promptly acknowledged and can be sent to:Syracuse Cancer Research Institute600 East Genesee StreetSyracuse, NY 13202GENERAL INFORMATION Hydrazine sulfate is an anti-cachexia drug which acts to reverse the metabolic processes of debilitation and weight loss in cancer and secondarily acts to stabilize or regress tumors. Every informed-consent, controlled clinical trial performed in accordance with internationally accepted standards of scientific conduct—without exception—has indicated efficacy and safety of the drug. The only contrary results, discussed below, have been the National Cancer Institute-sponsored studies, in which incompatible agents (medications) were used with the test drug. (The use of incompatible agents, in violation of the foregoing standards, acts to cause a negative study.)Hydrazine sulfate is a monoamine oxidase (MAO) inhibitor and is incompatible with tranquilizers, barbiturates, alcohol and other central nervous system depressants. Foods high in tyramine, such as aged cheese and fermented products, are also incompatible with MAO inhibitors. The use of tranquilizers, barbiturates and/or alcoholic beverages with hydrazine sulfate destroys the efficacy of this drug and represents a clear clinical hazard.The U.S. National Cancer Institute-published studies of hydrazine sulfate (Journal of Clinical Oncology, June 1994), which were reported as negative, denied the concurrent use of tranquilizers in general. However, under pressure of an investigation of the NCI-sponsored studies by the U.S. General Accounting Office ordered by Congress, the NCI admitted to the widespread use of both phenothiazine and the more powerful benzodiazepine tranquilizers—in 94% of all patients tested (Journal of Clinical Oncology, June 1995). Approximately half of these patients were administered these tranquilizers on a long-term basis, and some on a continual basis. It was further stated by the NCI that concomitant drug use—tranquilizers, alcohol, barbiturates, etc.—was not computerized and patient records of such drug use were “incomplete.”Hydrazine sulfate has been demonstrated to produce only few and transient side effects. There have been no instances of bone-marrow depression or of heart, lung or immune system toxicity. Hydrazine sulfate has never been shown to be carcinogenic—i.e., cause cancer—in humans.In its December 4, 2000 issue the respected medical journal Annals of Internal Medicine published a “Brief Communication” and editorial—in its journal and on the Internet—alleging “fatal hepatorenal failure” in a single patient due to hydrazine sulfate. However, there was no proof presented that the patient in question ever took hydrazine sulfate. The authors of the “Brief Communication” stated: “We could not obtain samples of the product he [the patient] ingested for laboratory analysis.” This means that there was no possibility of a direct examination of what it was the patient was taking. The authors further stated: “His blood was not tested for the presence of hydrazine.” But there are simple spectrofluorometric blood tests that can confirm even the tiniest residues of hydrazine sulfate ingested even months prior.It must be stressed that no medical journal anywhere—of high repute or not—would publish an article and editorial based on only one case, calling attention of the medical and lay public to the potential toxicity of a drug gaining in common use, without incontrovertible, verifiable, iron-clad proof that the patient in question ever took the drug in the first place. No journal would have the ethical recklessness to publish an article having far-reaching repercussions on the public health, without absolute proof of its basic, fundamental assumptions.The authors of the article and editorial, basing their warning of hydrazine sulfate toxicity to the liver and kidney on but one unverifiable patient, were nevertheless conversant with the large-scale National Cancer Institute-sponsored studies of hydrazine sulfate—in which hundreds of patients verifiably received the drug—which showed the complete absence of any organ toxicity, including liver and kidney: “There were no significant differences between the protocol treatment arms [hydrazine sulfate and placebo] with regard to myelodepression, gastrointestinal toxicity, renal toxicity, cardiopulmonary toxicity or neurotoxicity.”(Contrast this situation—in which a cancer “drug alert” is disseminated worldwide via the Internet based on unconfirmed use in a single patient—with the tens of thousands of authenticated drug deaths due to cancer chemotherapy each year. Yet no medical journal has seen fit to issue an Internet warning to the public of this truly legitimate hazard.)Hydrazine sulfate has been in clinical use since 1973. Thousands of study patients have been published in the medical literature. And many more thousands the world over have been treated by their individual doctors. There has not been a single case of hepatorenal failure ever reported.The Syracuse Cancer Research Institute therefore judges that the “drug alert” issued by the Annals of Internal Medicine in December 2000, in regard to hydrazine sulfate, is simply not credible.For a comprehensive discussion of hydrazine sulfate, please visit www.hydrazinesulfate.org, as given on the left border of the present Web site (“The Truth About Hydrazine Sulfate—Dr. Gold Speaks”)THE ELWOOD FUND Elwood was a beloved seventeen-year-old cat who passed away June 16,k 2005, of kidney failure. A sleek, short-hair female cat, Elwood made medical history and was responsible for the betterment of thousands of cats and dogs around the world. In 1997 Elwood had part of her stomach removed at Cornell University Veterinary Hospital for cancer; however, the edges sewn together were full of cancer and she was not expected to live long. She returned to the clinic six weeks later emaciated. She was placed on a course of chemotherapy to be given every three weeks and on daily hydrazine sulfate, an anticancer drug developed by the Syracuse Cancer Research Institute, and was given a prognosis of “two to five months.” The chemotherapy was discontinued after the second course because of side effects, and Elwood was maintained only on daily hydrazine sulfate. After the chemotherapy was discontinued, Elwood began to nibble, then eat vigorously. Until then, the longest-lived cat on record with her disease was one year. After one year, Elwood had regained all her lost weight, having been maintained only on daily hydrazine sulfate (and a steroid), and visited the clinic every six months for the next eight years. Word of her recovery spread throughout the nation, as a result of which thousands of cats and dogs were placed on hydrazine sulfate, many of whom were reported to have recovered completely.The Syracuse Cancer Research Institute has established the Elwood Fund, dedicated to the beneficial treatment of small animals with terminal disease, and to the dissemination of information to veterinarians and to owners of cats and dogs in regard to the therapy of these animals. Those wishing to contribute to the Elwood Fund are asked to send tax-deductible contributions to the Syracuse Cancer Research Institute, Elwood Fund, 600 E. Genesee Street, Syracuse, NY 13202. All contributions will be acknowledged.For further information please call or have your health care professional call the institute between 9:00 AM and 5:00 PM Eastern time, weekdays, (315)472-6616, 472-6618, 472-2229.This page is designed and hosted by NGEN and is the property of the Syracuse Cancer Research Institute © 1996-2005, Syracuse Cancer Research Institute. All rights reserved. Last modified on 28 November 2005